Navigation Links
Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
Date:9/14/2010

Phase 3 trials and their relationship to outcome.  These data show that the cure rate among patients harboring BI isolates was significantly lower than those with non-BI strains (86.5% vs. 94.3%, p=0.0006) and that the recurrence rate was significantly higher for those with the BI strain versus the non-BI strains (27.3% vs. 16.6%, p=0.003).  In the trials, the BI strain of Clostridium difficile was the major strain type (39%) in North America but the BI strain was not nearly as frequent in Europe (10%). In the non-BI group recurrence rates were significantly lower in  patients treated with fidaxomicin versus patients treated with vancomcyin (8.4% vs. 25.3%, p<0.001).  In the BI group fidaxomicin showed a clinically meaningful 25% reduction in recurrence rates compared to vancomycin (23.3% vs 31.2%).Clinical investigator, Mark A. Miller, M.D., head of the Division of Infectious Diseases, Chair of the Infection Prevention and Control Unit at the Jewish General Hospital in Montreal, Quebec, Canada, presented analyses on a bedside scoring system for assessing CDI risk factors. There is currently no validated bedside risk assessment tool to categorize patients or predict CDI cure or recurrence. Using data from Optimer's first fidaxomicin Phase 3 trial, researchers evaluated a scoring system composed of five simple patient risk factors:  Age, Temperature (T), Leukocytosis (WBC), Albumin (Alb), and Concomitant Systemic Antibiotics (SA).  These five bedside risk factors were combined to correlate with CDI cure, recurrence, and global cure.  Dr. Miller recommended that this scoring system should be validated on other databases of CDI patients in order to assist in predicting CDI cure, recurrence, morbidity, and mortality.  

For a complete list of posters, please visit the Resources page on our website at: www.optimerpharma.com

Fidaxomicin Clinica
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
2. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
3. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
4. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
6. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
7. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
8. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
9. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
10. Stemedica Announces Completion of Clinical Stem Cell Master Bank
11. DATATRAK International, Inc. Announces Initial Equity Research Coverage by Zacks Investment Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Unraveling life’s mysteries ... The Archer Family purchased a DNA test ... but ended up with a lifetime of memories, sharing, ... the family members’ DNA genuinely brought the family closer ... search deeper into genetic history and prior to taking ...
(Date:7/10/2014)... OMICS Group’s 5th International conference and ... 2014 at Double Tree by Hilton Beijing, China is ... Analytical & Bioanalytical research methods only to facilitate improved ... occasion, Dr. Srinubabu Gedela, MD of OMICS Group Inc ... remarkable one in bringing a unique and international mix ...
(Date:7/10/2014)... Senior supply chain management executives from ... the challenges of “Reducing Cost, Lead Time, & Defects ... sourcing. Describing the partnership of the Bio Supply Management ... Institute ( SCMI) of the University of San ... the Kroc Institute of Peace and Justice in San ...
(Date:7/10/2014)... 10, 2014 On July 9 ... , presented Russia,s first national ... The Company is developing a unique project called ... develops a number of innovative drugs based on monoclonal ... ceremony took place at the International Exhibition "Innoprom 2014" ...
Breaking Biology Technology:Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2
... batch of bluetongue Bovilis BTV8 vaccine released to supply Northern ... ... Animal Health (NYSE: SGP ) released the first batch,of Bovilis ... company, combining after the acquisition in 2007 the,strength of Intervet and ...
... Lechleiter,Ph.D., president and CEO of Eli Lilly and ... for its investment in biotechnology and provided insight ... for ensuring the state,s significant,investment is rewarded. He ... gathering of policymakers, business leaders and academics,under the ...
... RATON, Fla., April 30 Siemens Communications, ... achievement awards. The,winners, members of the Siemens ... Siemens Enterprise Partner Forum held in March ... ), The Siemens Enterprise Partner ...
Cached Biology Technology:Intervet/Schering-Plough Animal Health Outlines Strength of the Combination 2Intervet/Schering-Plough Animal Health Outlines Strength of the Combination 3Lilly CEO Praises Massachusetts' Leadership in Biotech, Urges Policy Prescriptions to Help Ensure State's Investment Generates Dividends and Jobs 2Lilly CEO Praises Massachusetts' Leadership in Biotech, Urges Policy Prescriptions to Help Ensure State's Investment Generates Dividends and Jobs 3Black Box Network Services, ABTECH, Verizon Business and Wyle Named Top Siemens Reseller Partners 2Black Box Network Services, ABTECH, Verizon Business and Wyle Named Top Siemens Reseller Partners 3Black Box Network Services, ABTECH, Verizon Business and Wyle Named Top Siemens Reseller Partners 4
(Date:7/11/2014)... at the Department of Energy,s Oak Ridge National ... by R&D Magazine in recognition of the year,s ... the tremendous value of our National Labs," said ... at the National Labs continues to help our ... scientific and technological innovations necessary to remain globally ...
(Date:7/11/2014)... American Society for Bone and Mineral Research awarded Michael ... Medicine (BUSM), with the 2014 Louis V. Avioli Award. ... BUSM, is internationally known for revolutionizing the understanding of ... , The award honors a member of the American ... contributions to bone and mineral basic research. It is ...
(Date:7/11/2014)... Cell scientists have set a "mouse TRAP" to capture ... a recent study published in the Journal of ... a technique called TRAP to extract cellular and genetic ... by scientists at the Rockefeller Institute for Medical Research ... the protein-making machinery, or ribosomes, of the cell type ...
Breaking Biology News(10 mins):ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2
... hundred years, cocoa has been the black gold of ... often darkened the pages of history. Now, a partnership ... farmers benefit from the cocoa trade., Mars Incorporated, in ... partners, will increase the production of cocoa for smallholder ...
... Pittsburgh, PAAn international team of researchers, including Carnegie ... resolved the evolutionary relationships of Necrolestes patagonensis ... to its burrowing and underground lifestyle. This much-debated ... paleontological riddle for more than 100 years. Scientific ...
... 19, 2012 Deciphering what causes the brain cell degeneration ... But a team led by scientists from The Scripps Research ... brain cells in a mouse model of Parkinson,s disease. The ... be useful in preventing the actual condition. The team, ...
Cached Biology News:Making chocolate an affordable luxury 2After 121 years, identification of 'grave robber' fossil solves a paleontological enigma 2After 121 years, identification of 'grave robber' fossil solves a paleontological enigma 3After 121 years, identification of 'grave robber' fossil solves a paleontological enigma 4After 121 years, identification of 'grave robber' fossil solves a paleontological enigma 5Scripps Research Institute team identifies a potential cause of Parkinson's disease 2Scripps Research Institute team identifies a potential cause of Parkinson's disease 3
Human peripheral blood CD56+ NK cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
... Novagen's HT96 Isothermal Block is an ... hold HT96 plates and to provide efficient ... plate. This new design of the HT96 ... offers an enhanced product design allowing for ...
Plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Dendritic Cells...
Umbilical cord blood neutrophils, For immunohistochemistry (IHC)...
Biology Products: